Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Y-Trap’s lead PD-L1-targeted fusion protein demonstrated superior inhibition of tumor growth compared to clinically used PD-L1 antibodies in preclinical models, including efficacy in tumors resistant to current checkpoint inhibitors. The company is developing a family of multifunctional molecules based on its proprietary platform, with broad potential for improving cancer immunotherapy outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Y-Trap.